Bristol-Myers Squibb Compnay

George V De Lucca

Douglas G Batt

Percy H Carter

Jingwu Duan

Chunjian Liu

Joseph Anthony Tino

Dean A Wacker

John T Hynes

Wayne D Vaccaro

Soo Sung Ko

Scott Hunter Watterson

John E Starrett, Jr

Derek J Norris

Wen-Ching Han

Cullen L Cavallaro

Qingjie Liu

Hong Wu

Andrew P Degnan

Qing Shi

Andrew J Tebben

Anurag S Srivastava

Charles Malcolm Langevine

Michael A Galella

Feng Qiu

Matthew D Hill

Godwin Kwame Kumi

Gregory D Brown

William D Schmitz

Myra Beaudoin Bertrand

Jeffrey A Deskus

Hong Huang

Mikkel V DeBenedetto

Rui-Qin Liu

Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: Ris F, Cl, &#x2014;CN, or &#x2014;CH; Ris Cl or &#x2014;CH; Ris &#x2014;C(CH)OH or &#x2014;CHCHOH; Ris H or &#x2014;CH; each Ris independently F, Cl, &#x2014;CH, and/or &#x2014;OCH; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Substituted tetrahydrocarbazole and carbazole carboxamide compounds

The present application describes modulators of MIP-1&#x3b1; of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, T, W, R, R, R, Rand Rare as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.

Piperazinyl derivatives as modulators of chemokine receptor activity

Disclosed are nicotinamide compounds of Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. Also disclosed are methods of using such compounds in the treatment of at least one Btk associated condition, such as, for example, inflammatory disease, and pharmaceutical compositions comprising such compounds. 

Nicotinamide compounds useful as kinase modulators

The present application describes modulators of MCP-1 or CCR-2 of formula, (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein T, W, X, Y, Z, R, R, Rand R, are defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula, (I) are disclosed. 

Cyclohexenyl modulators of chemokine receptor activity

A compound of Formula (I) or Formula (II) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) or Formula (II), and methods of treating conditions associated with the activity of p38 kinase. 

Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors

The present application describes modulators of CCR3 of formula (Ia) and (Ib): or pharmaceutically acceptable salt forms thereof, wherein Z, R, R, R, R, R, R', R, a, b, c, d, and u are as defined herein in the specification. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using modulators of formula (Ia) and (Ib) are disclosed.

Substituted spiro azabicyclics as modulators of chemokine receptor activity

Growing community of inventors

Pennington, NJ, United States of America

George V De Lucca